Compounds > atrasentan
Page last updated: 2024-09-04

atrasentan and paclitaxel

atrasentan has been researched along with paclitaxel in 6 studies

Compound Research Comparison

Studies
(atrasentan)		Trials
(atrasentan)		Recent Studies (post-2010)
(atrasentan)		Studies
(paclitaxel)		Trials
(paclitaxel)		Recent Studies (post-2010) (paclitaxel)
3584110831,8745,72915,395

Protein Interaction Comparison

ProteinTaxonomyatrasentan (IC50)paclitaxel (IC50)
Integrin beta-3Homo sapiens (human)0.034
Integrin alpha-V Homo sapiens (human)0.034
ATP-dependent translocase ABCB1Homo sapiens (human)2.598
Botulinum neurotoxin type A Clostridium botulinum5.2
UDP-glucuronosyltransferase 2B7Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1-6Homo sapiens (human)4.9
Substance-K receptorHomo sapiens (human)6.125
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1A4Homo sapiens (human)4.9
UDP-glucuronosyltransferase 2B10 Homo sapiens (human)4.9
Delta-type opioid receptorHomo sapiens (human)4.202
Tyrosine-protein kinase MerHomo sapiens (human)4.9
Tubulin beta-3 chainHomo sapiens (human)0.0082
Beta-tubulin Leishmania donovani1
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)7.9433
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)0.26
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.28

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's5 (83.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chiou, WJ; Dickinson, R; Opgenorth, TJ; Wu-Wong, JR1
Bagnato, A; Cirilli, A; Muller, A; Natali, PG; Nicotra, MR; Salani, D; Simeone, P; Venuti, A1
Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Salani, D; Spinella, F; Venuti, A1
Bagnato, A; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F1
Antonia, S; Bepler, G; Boulware, D; Burton, M; Chiappori, AA; Haura, E; Kapoor, R; Lush, R; Neuger, AM; Padilla, B; Rodriguez, FA; Simon, G; Sullivan, DM; Williams, C1
Azim, HA; Mok, T1

Reviews

1 review(s) available for atrasentan and paclitaxel

ArticleYear
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life.
    Anti-cancer drugs, 2008, Volume: 19, Issue:6

    Topics: Atrasentan; Cisplatin; Diphosphonates; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Receptors, Calcitriol; Taxoids

2008

Trials

1 trial(s) available for atrasentan and paclitaxel

ArticleYear
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate

2008

Other Studies

4 other study(ies) available for atrasentan and paclitaxel

ArticleYear
Endothelin attenuates apoptosis in human smooth muscle cells.
    The Biochemical journal, 1997, Dec-15, Volume: 328 ( Pt 3)

    Topics: Angiotensin II; Annexin A5; Apoptosis; Atrasentan; Cell Survival; DNA Fragmentation; Endothelin Receptor Antagonists; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Male; Muscle, Smooth; Paclitaxel; Pericardium; Phosphatidylserines; Propidium; Prostate; Pyrrolidines

1997
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.
    Cancer research, 2002, Nov-15, Volume: 62, Issue:22

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Cell Division; Drug Synergism; Endothelin Receptor Antagonists; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays

2002
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Cancer research, 2003, May-15, Volume: 63, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Division; Drug Synergism; Endothelial Growth Factors; Endothelin Receptor Antagonists; Female; Growth Inhibitors; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays

2003
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.
    Journal of cardiovascular pharmacology, 2004, Volume: 44 Suppl 1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Line, Tumor; Cisplatin; Endothelin A Receptor Antagonists; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Time Factors; Xenograft Model Antitumor Assays

2004